The companies will combine the Binx io diagnostic platform with Sherlock Bio's CRISPR technology to create an easy-to-use rapid test for the point of care.
Sherlock Bio recently received US Food and Drug Administration Emergency Use Authorization for the kit, which uses CRISPR to detect the virus in patient samples.
